STOCK TITAN

DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

DarioHealth Corp. (Nasdaq: DRIO) announced it will release its Q3 2024 financial results on Thursday, November 7th, 2024, before market opens. The company will host a conference call and webcast at 8:30 AM ET, led by CEO Erez Raphael and CCO Steven Nelson. The earnings call will be accessible via phone dial-in and webcast, with replay available until November 21, 2024.

DarioHealth Corp. (Nasdaq: DRIO) ha annunciato che pubblicherà i suoi risultati finanziari del Q3 2024 giovedì 7 novembre 2024, prima dell'apertura del mercato. La società ospiterà una conference call e un webcast alle 8:30 AM ET, guidati dal CEO Erez Raphael e dal CCO Steven Nelson. La chiamata sugli utili sarà accessibile tramite telefonata e webcast, con la registrazione disponibile fino al 21 novembre 2024.

DarioHealth Corp. (Nasdaq: DRIO) anunció que publicará sus resultados financieros del Q3 2024 el jueves 7 de noviembre de 2024, antes de la apertura del mercado. La empresa realizará una conferencia telefónica y un webcast a las 8:30 AM ET, liderados por el CEO Erez Raphael y el CCO Steven Nelson. La llamada de ganancias será accesible por teléfono y webcast, con una repetición disponible hasta el 21 de noviembre de 2024.

DarioHealth Corp. (Nasdaq: DRIO)는 2024년 11월 7일 목요일 시장 개장前에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 CEO Erez Raphael과 CCO Steven Nelson이 이끄는 오전 8시 30분(ET)에 컨퍼런스 콜 및 웹캐스트를 주최할 예정입니다. 실적 발표 콜은 전화 접속 및 웹캐스트를 통해 접근 가능하며, 재생은 2024년 11월 21일까지 가능합니다.

DarioHealth Corp. (Nasdaq: DRIO) a annoncé qu'elle publiera ses résultats financiers du T3 2024 le jeudi 7 novembre 2024, avant l'ouverture du marché. L'entreprise tiendra une conférence téléphonique et un webcast à 8h30 ET, animés par le PDG Erez Raphael et le CCO Steven Nelson. L'appel de résultats sera accessible par téléphone et webcast, avec un replay disponible jusqu'au 21 novembre 2024.

DarioHealth Corp. (Nasdaq: DRIO) hat angekündigt, dass es seine finanziellen Ergebnisse für das Q3 2024 am Donnerstag, den 7. November 2024, vor Markteröffnung veröffentlichen wird. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, geleitet von CEO Erez Raphael und CCO Steven Nelson. Der Gewinnanruf wird sowohl telefonisch als auch über Webcast zugänglich sein, mit einer Wiederholung bis zum 21. November 2024 verfügbar.

Positive
  • None.
Negative
  • None.

Company to host conference call and webcast at 8:30am ET

NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens.

 

DarioHealth Corp. Logo

 

Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.

Conference Call Details

Date: Thursday, November 7th, 8:30am ET

Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

Call me™: https://emportal.ink/3SOTLAn

Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.

Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1685062&tp_key=51068b0c30

Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion of the conference call through Thursday, November 21, 2024. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1131131.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a global digital health company dedicated to transforming the way people manage chronic conditions through its user-centric, multi-condition digital therapeutics platform. Dario's comprehensive platform leverages data analytics, AI, and personalized coaching to deliver continuous care for diabetes, hypertension, musculoskeletal health, weight management, and behavioral health. By empowering individuals to take control of their health through behavior change, Dario is revolutionizing the digital health landscape.

For more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected date of its earnings release. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280

DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922

Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630

Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

 

 

Cision View original content:https://www.prnewswire.com/news-releases/dariohealth-to-report-third-quarter-2024-results-on-thursday-november-7th-302284347.html

SOURCE DarioHealth Corp.

FAQ

When will DarioHealth (DRIO) report Q3 2024 earnings?

DarioHealth will report its Q3 2024 earnings on Thursday, November 7th, 2024, before the market opens.

How can I access DarioHealth's (DRIO) Q3 2024 earnings call?

You can access the earnings call on November 7th at 8:30 AM ET via phone (1-800-717-1738 domestic, 1-646-307-1865 international), Call me™ link, or webcast.

Until when will DarioHealth's (DRIO) Q3 2024 earnings call replay be available?

The earnings call replay will be available until Thursday, November 21, 2024, accessible via 1-844-512-2921 (domestic) or 1-412-317-6671 (international) using passcode 1131131.

DarioHealth Corp.

NASDAQ:DRIO

DRIO Rankings

DRIO Latest News

DRIO Stock Data

27.93M
30.03M
14.28%
27.47%
5.9%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK